| If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| | | ![]() FDA Approves Drug to Prevent Joint Damage in Children with Haemophilia A ROCKVILLE, Md -- October 10, 2008 -- The US Food and Drug Administration (FDA) has approved a new use for antihemophilic factor recombinant (Kogenate FS) to reduce the frequency of bleeding episodes and prevent joint damage in children with haemophilia A. "Administering [the drug] to children with haemophilia A on a daily basis before a bleeding event occurs will reduce bleeding into joints and help prevent joint damage, a major cause of disability in haemophiliacs," said Jesse Goodman, MD, FDA's Center for Biologics Evaluation and Research, Rockville, Maryland. In a clinical trial, 65 boys aged less than 30 months with severe haemophilia A and normal joints were observed for 5 years. The patients received either 1 daily dose of the drug or 3 doses at the time of a bleeding episode. Joint damage during a bleeding episode was 6-fold lower, and the rate of bleeding 8-fold lower, in those boys who received the drug on a daily basis compared with those who received the drug only when a bleeding episode occurred. Most patients received the drug intravenously through a catheter. The most common adverse events were infection at the catheter site and fever. SOURCE: US Food and Drug Administration
|